{"entity":{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","aka":[],"tldr":"In EPCORE NHL-1, the off-the-shelf bispecific antibody epcoritamab, injected under the skin, produced responses in 63% of 157 patients with relapsed large B-cell lymphoma, including the 39% whose CAR-T had failed. Cytokine release syndrome occurred in half, mostly mild, and the drug won accelerated approval in 2023.","summary":"The dose-expansion part of EPCORE NHL-1 treated 157 patients with relapsed or refractory large B-cell lymphoma after at least two prior lines (median three; 39% had prior CAR-T) with subcutaneous epcoritamab given with step-up dosing then weekly, fortnightly and monthly. The overall response rate was 63.1% with complete response in 38.9%; median duration of response was 12.0 months and complete responders had durable remissions. CRS occurred in 49.7% (grade 3 in 2.5%) and ICANS in 6.4% with one fatal event. Responses were similar after CAR-T failure. Epcoritamab received accelerated approval in 2023, alongside the intravenous CD20 x CD3 bispecific glofitamab, whose pivotal study reported complete response in 39% of 155 patients.","asOf":"2026-09-08","links":[{"label":"PubMed search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPCORE%20NHL-1%20epcoritamab%20large%20B-cell%20lymphoma%20Thieblemont%20JCO%202023"},{"label":"ClinicalTrials.gov NCT03625037","url":"https://clinicaltrials.gov/study/NCT03625037"}],"tags":[],"related":["bispecific-plus-adc-lymphoma"],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["cd20","cd3"],"drugs":["epcoritamab","glofitamab","mosunetuzumab","odronextamab"],"companies":["abbvie","roche-genentech"],"institutions":[],"pathways":[],"terms":["crs","icans","orr"],"trials":["epcore-nhl-1","epcore-dlbcl-1","starglo"],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-resistance"],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.22.01725","pmid":"36548927","authors":"Thieblemont C, Phillips T, Ghesquieres H, et al.","paperType":"translational","findings":["157 patients with relapsed/refractory LBCL after 2 or more lines; 38.9% had prior CAR-T.","Overall response 63.1%; complete response 38.9%.","Median duration of response 12.0 months; most complete responses ongoing at data cut.","CRS 49.7% (grade 3 2.5%), largely confined to cycle 1; ICANS 6.4% (one fatal).","Similar response rates in patients whose CAR-T had failed."],"whatItMeans":"CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.","caveats":["Single-arm phase 2; randomised confirmation in earlier lines came later with mixed results in some designs.","Fixed-duration (glofitamab) versus until-progression (epcoritamab) dosing remains a practical difference without head-to-head data.","Infection risk and hypogammaglobulinaemia accumulate with prolonged dosing.","Durability of partial responses is limited."],"changedPractice":true,"participants":157},"route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","neighbours":{"pairing":[{"id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"},{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"term":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/"},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/"}],"trial":[{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/"},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/"},{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}],"person":[{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/"}]}}